Therapeutic Response

v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Papillary Thyroid Cancer.

Statements

Source and description
Retsevmo (selpercatinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).